Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial
Gelhorn, HL et al. Patient. 2026:.https://doi.org/10.1007/s40271-026-00840-3.
A mixed-method analysis characterized improvements in physical functioning among patients with tenosynovial giant cell tumor treated with vimseltinib who were considered physical functioning responders in the Phase 3 MOTION study. PROMIS-PF assessments and in-trial exit interviews showed meaningful improvements, including better mobility, greater independence, and the ability to resume work, daily activities, and recreational activities.
You can access the publication here.
DCPH-M01358v1 11/2026